SCHEMBL23329217

SCHEMBL23329217

OCc1[nH]nnc1-c1ccc(-c2cccc(-c3ccccc3)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GP6 Q9HCN6 2/20 0.41
▸ MKNK1 Q9BUB5 1/20 0.38
▸ FGFR1 P11362 2/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ PRKCI P41743 1/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ MAPT P10636 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ HTT P42858 1/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ KMO O15229 1/20 0.35
▸ ACMSD Q8TDX5 1/20 0.35
▸ DYRK3 O43781 1/20 0.35
▸ CLK1 P49759 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23328899 0.85 ESR1 (0.45) ESR1ALDH1A1HPGDNPSR1ALOX5
SCHEMBL23329080 0.79 MKNK1 (0.55) MKNK1FGFR1KDM4EMAPTALDH1A1
SCHEMBL23328939 0.78 HDAC8 (0.41) MAPTALDH1A1HPGDACMSD
SCHEMBL23329267 0.76 KDM4E (0.41) KDM4EALDH1A1HPGDHSD17B10HTT
SCHEMBL31246119 0.75 KMO (0.46) GP6MKNK1KDM4EKMOACMSD
SCHEMBL23303650 0.75 KMO (0.46) GP6MKNK1KDM4EKMOACMSD
SCHEMBL23329266 0.74 NPC1 (0.45) GSK3BDYRK1ACLK4NPC1
SCHEMBL27483035 0.73 ALOX15 (0.39) KDM4EMAPTALDH1A1HPGDNPSR1
SCHEMBL28147077 0.73 DPP4 (0.40) KDM4EMAPTALDH1A1HPGDNPSR1
SCHEMBL14498353 0.73 PTGS1 (0.40) MEN1KMT2AKDM4EMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 — — US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO GP6 1181/4885MKNK1 3973/4885FGFR1 1824/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO GP6 1181/4885MKNK1 3973/4885FGFR1 1824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback